Supplementary Figure 7 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Association of tumor burden with cancer mutation concentration (CMC), as well as cancer-specific methylation (CSM) and fragment length score (FLS). We computed CMC from personalized tumor-informed mutation arrays. We also computed CSM and FLS from methylation and fragmentomic analysis respectively of data from cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq) assays. Coefficients and p-values were computed using Spearman correlations.